In an effort to support global initiatives to contain the spread of the new coronavirus (COVID-19), the Academy is presenting Spring 2020 events through online platforms and some of our previously scheduled events are being postponed to a later date. Please check our events listing for the latest information and contact our Customer Service team with any additional questions. For Academy programs and resources about COVID-19, click here.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.


Oligonucleotide Therapeutics (1)

Edited by Edited by John Rossi (Beckman Research Institute of the City of Hope, Duarte, California), Michael Gait (Medical Research Council, Cambridge, UK), and Fritz Eckstein (Max-Planck Institute for Experimental Medicine, Göttingen, Germany)
Oligonucleotide Therapeutics (1)

Published: September 2009

Volume 1175

This Annals volume presents new technologies in the field of oligonucleotide research by basic researchers in molecular biology, cell biology, nucleic acid chemistry, pharmacology, and applied therapeutics .
Learn More

Oligonucleotides modulate gene-specific expression within cells and can be used to identify genes involved in diseases. Continuing developments in oligonucleotide research have begun to unleash their potential as therapeutic agents. This volume focuses on small RNA-mediated gene silencing, micro RNA (miRNA), oligonucleotide chemistry and new technologies, delivery strategies, immunorecognition of nucleic acids, drug and therapeutic development, aptamers and other evolved systems, and preclinical models and clinical programs.